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Abstract 
OBJECTIVE  
To compare foam bubble size and bubble size distribution, stability, and degradation rate (DR) of 
commercially available polidocanol endovenous microfoam (Varithena
®
) and physician
compounded foams (PCFs) using a number of laboratory tests.   
METHODS 
Foam properties of polidocanol endovenous microfoam and PCFs were measured and compared 
using a glass plate method and a Sympatec QICPIC image analysis method to measure bubble 
size and bubble size distribution, Turbiscan™ LAB for foam half time and drainage, and a novel 
biomimetic vein model to measure foam stability. PCFs composed of polidocanol and room air 
(RA), CO2, or mixtures of oxygen and carbon dioxide (O2:CO2) were generated by different 
methods.  
RESULTS  
Polidocanol endovenous microfoam was found to have a narrow bubble size distribution with no 
large (>500 µm) bubbles. PCFs made with the Tessari method had broader bubble size 
distribution and large bubbles, which have an impact on foam stability. Polidocanol endovenous 
microfoam had a lower degradation rate (DR) than any PCFs, including foams made using RA 
(p<0.035). The same result was obtained at different liquid to gas ratios (1:4 and 1:7) for PCFs. 
In all tests performed, CO2 foams were the least stable and different O2:CO2 mixtures had 
intermediate performance. In the biomimetic vein model, polidocanol endovenous microfoam 
had the slowest DR, and longest calculated dwell time, which represents the length of time the 
foam is in contact with the vein, almost twice that of PCFs using RA and eight times better than 
PCFs prepared using equivalent gas mixes.  
CONCLUSION  
Bubble size, bubble size distribution, and stability of various sclerosing foam formulations show 
that polidocanol endovenous microfoam results in better overall performance compared with 
PCFs. Polidocanol endovenous microfoam offers better stability and cohesive properties in a 
biomimetic vein model compared to PCFs. Polidocanol endovenous microfoam, which is 
indicated in the United States for treatment of great saphenous vein system incompetence, 
provides clinicians with a consistent product with enhanced handling properties.  
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Introduction 
Physician-compounded foams (PCFs) have been introduced in vein treatment with the aim of 
increasing efficacy and treating larger varicose veins relative to liquid sclerosants.
1, 2
 However,
foams are not all the same and, in fact, they can be dramatically different from each other. The 
performance of foams is highly dependent on their physical characteristics: gas composition, the 
different absorption rates of nitrogen and carbon dioxide in the bloodstream, and bubble size.
3-5
PCFs offer several advantages over traditional liquid sclerosants. When injected into a vein, a 
cohesive foam displaces the blood (rather than mixing with it), creating better contact with the 
vein wall. Foam treatment offers the possibility of using lower sclerosant concentrations.
6
 This,
in turn, increases the safety of foam treatment as shown in clinical trials.
7-9
 Furthermore, foam is
echogenic, which improves visibility and treatment accuracy.
10
 Also, foam treatment can be
performed in an outpatient setting without need for sedation or tumescent anesthesia.
11
Foam treatment also presents challenges. Room air (RA) forms stable foam, but because the 
nitrogen it contains does not dissolve efficiently in blood, nitrogen bubbles may persist and can 
cause adverse effects.
12, 13
 Carbon dioxide (CO2) foams can be made, but the increased solubility
results in foams that coarsen rapidly, leading to drastically reduced stability. PCF methods may 
generate large gas bubbles that may be potentially problematic in the circulation. Strategies such 
as using CO2 rather than RA and limiting the injected volume of PCF to less than 10 mL have 
been proposed to reduce the incidence of serious complications, since significant neurological 
events have occurred after injections of as little as 4 mL of PCF. These neurological events have 
been attributed to nitrogen/air.
14-16
 In fact, two reports have documented that all patients injected
with PCF for the treatment of venous varicosities have gas bubbles visible in the right heart 
chambers, and some patients, such as those with patent foramen ovale (PFO) or other right-to-
left shunts, have gas bubbles in the left heart chambers.
17, 18
The two most popular techniques that clinicians use to generate PCFs are the Double Syringe 
System (DSS) and the Tessari method.
19, 20
 DSS involves passing the sclerosant liquid and gas
between two syringes joined by a simple straight connector (Figure 1a). The Tessari method is 
similar, but the straight connector is replaced with a 3-way valve (Figure 1b). Although these 
two methods are very similar, the DSS method is felt to produce slightly better foam.
21
Polidocanol endovenous microfoam (Varithena
®
 [polidocanol injectable foam 1%], Provensis
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Ltd, a BTG International group company) is a new product designed to overcome the challenges 
associated with PCFs. Polidocanol endovenous microfoam is generated by a proprietary device 
that produces consistent, pharmaceutical-grade low nitrogen (<0.8%), O2:CO2 (65:35) foam 
(Figure 1c). In a recent case series of sixty patients with middle cerebral artery bubble emboli 
during or after treatment with PEM, no evidence of subclinical cerebral injury was found on 
MRI.
22
 In addition, in two pivotal Phase 3 clinical trials using polidocanol endovenous
microfoam, there were no clinically meaningful neurologic adverse events observed.
23
Methods for measuring bubble size and size distribution include the Sympatec image analysis 
sensor QICPIC (Sympatec Ltd., Bury, Lancashire, UK) and Turbiscan™ LAB apparatus 
(Formulaction SAS, L’Union, France) (Figure 2). Sympatec provides a bubble size distribution 
of flowing microbubbles in deionized water, whereas Turbiscan™ provides dynamic information 
on foam. The speed at which liquid separates from the body of foam has been used as a measure 
of foam stability.
24
 Foam drainage time (FDT) and rate are good measures of foam stability.
21
Methods for measuring foam stability and cohesiveness include the Turbiscan™ LAB operated 
in the scanning detector mode for foam drainage kinetics and foam half time (FHT), and 
operated in the fixed detector mode for FDT determination. The novel biomimetic analysis 
system was developed for the quantification of foam properties under clinically relevant 
conditions to establish a robust method for comparative characterization of polidocanol 
endovenous foam and PCFs. The high resolution computational video analysis system allows 
accurate quantification of foam dynamic behavior, including foam plug expansion rate, 
degradation rate and dwell time (Figure 3).
25
This paper reports the results of a number of tests performed to compare foam bubble size and 
bubble distribution, stability, and degradation rate of polidocanol endovenous foam and PCFs. 
These foams were also investigated in the biomimetic vein model to relate stability to clinical 
function. 
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Materials and Methods 
Foam Production and Characterisation 
Full details about foam production and characterisation methods are provided in the 
Supplementary Information sections S1 and S2, respectively. 
For preparation of PCFs, one percent (1%) aqueous buffered polidocanol solution was used 
throughout these studies. Foam densities were at a liquid to gas ratio of 1:7 for direct comparison 
with PEM or at 1:4 to represent commonly used formulations. DSS and Tessari methods were 
used to create PCFs. 
Polidocanol endovenous microfoam consists of a proprietary O2:CO2 (65:35) gas mixture with 
ultra-low nitrogen content (<0.8%) and 1% polidocanol solution contained within a pressurized 
canister and combined on discharge as uniform microfoam. Sterile canisters of the product were 
used to generate 5 mL of microfoam for experimentation. 
Foam properties of polidocanol endovenous microfoam and PCFs were measured and compared 
using glass plate method and Sympatec QICPIC image analysis to measure bubble size and 
bubble size distribution, Turbiscan™ LAB apparatus for foam half time (FHT) and foam 
drainage time (FDT), and the biomimetic vein model to measure foam stability. These are 
summarised in Table I, and methodological details are reported in the Supplementary 
Information section S2. 
Statistical Analysis 
One-way analysis of variance (ANOVA) was performed to analyze the differences between 
group means using OriginPro (Origin Lab Corp., Northampton, MA) software package. Pairwise 
comparison tests were performed using the Bonferroni method. The significance level was set to 
0.05 (i.e., differences were considered to be statistically significant for p-value < 0.05). The 
number of experimental repeats for each test is reported in Table II. Selected relevant p-values 
for comparison between PEM and PCFs using the different methods are shown in Table III. 
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Results 
Comparison of Methods Used to Measure Bubble Size Distribution 
Figure 4 provides a visual comparison of the bubble images captured using the glass plate and 
the Sympatec methods and the frequency of bubble size measured by these two methods for 
polidocanol endovenous microfoam. The glass plate method shows a closely-packed foam 
(Figure 4a) and measures a relatively tightly distributed bubble size distribution with no bubbles 
>~300 µm in diameter (Figure 4b). The captured image from the Sympatec shows the bubbles 
are no longer in close contact with one another at the point of measurement, having been 
separated in the flowing carrier liquid (Figure 4c). This method over-reports the true bubble size 
with bubbles up to ~600 µm, and bubbles smaller than 15 µm in diameter are not detectable 
because of foam coarsening during the time taken to administer the foam into the instrument, and 
loss of smaller bubbles before they reach the detector in the instrument (Figure 4d). 
Bubble Size Distributions of Various Foam Formulations 
Figure 5 shows the distribution of bubble sizes (in terms of volume fraction) generated using the 
Sympatec method for PCFs (liquid:gas ratio of 1:7) produced using RA, O2:CO2 (35:65) and 
CO2, and the DSS and Tessari foam preparation methods. Initial bubble size distribution for 
prepared foams is narrowest for RA<O2:CO2<CO2 for PCFs produced by either preparation 
method. The Tessari method clearly generates more large bubbles compared to the DSS method 
regardless of the gas mixture used.  
When polidocanol endovenous microfoam bubble size distribution is compared to a PCF made 
with the same gas mixture [O2:CO2 (65:35)] and liquid:gas ratio (1:7) using either the DSS or 
Tessari methods, there is clearly a narrower bubble size distribution for polidocanol endovenous 
microfoam when measured using the Sympatec method 40 and 115 seconds after foam 
preparation (Figure 6). Generally, the contrast is more pronounced when polidocanol 
endovenous microfoam is compared with the other O2:CO2 PCFs made with higher CO2 content 
(Figure 6a versus Figure 5b-5f). A greater number of larger bubbles were present for PCFs, 
particularly using the Tessari method. At 40 seconds, polidocanol endovenous microfoam bubble 
size distribution is similar to RA (maximum bubble size <500 µm by this method) and at 115 
seconds only slightly broader than RA for foams produced using the DSS method (Figure 6a 
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7 
versus 5a) and without the large bubbles present for RA made by the Tessari method (Figure 6a 
versus 5d). 
Foam Drainage Time (FDT) 
Foam drainage time (FDT) is an important indicator of foam stability.
21
 Essentially, if the foam
drains rapidly, it will coarsen and degrade more rapidly; the cohesiveness of the foam will be of 
short duration and, thus, there will be less time for the drug to be in contact with the vessel wall 
because the degrading foam will not be able to properly displace the blood in the vessel lumen. 
In this test method, the FDT is the time at which light transmission is detected at the bottom of 
the foam column. Figure 7a shows the percent transmission of light through the foam over a 
period of time. For 100% CO2, the foam drains very quickly and so light passes through the 
liquid layer almost immediately as indicated by the blue curve in the image. At a 30:70 O2:CO2 
composition (red curve), the resulting foam also drains very quickly, but the curve does not 
inflect upward until the 45 second mark, as the foam is more stable and therefore drains more 
slowly than foam made with 100% CO2. RA foam (black curve) is most stable and takes 
approximately 165 seconds before light begins to transmit through the draining liquid.  FDT is 
shown for polidocanol endovenous microfoam compared with the DSS vs Tessari foams 
produced with different gas compositions, and 1:7 liquid:gas ratio (Figure 7b). In general, FDT is 
longer for DSS-prepared PCFs against the Tessari, with the difference becoming greater as the 
CO2 levels in the foams decrease and the foams become more stable. The FDT of polidocanol 
endovenous microfoam is greater than any combination of gas mixture and method of 
preparation, with the exception of RA using the DSS method. Figure 7c shows the FDT for PEM 
and PCFs produced using the DSS method with two different liquid-to-gas ratios (1:7 and 1:4). 
The FDT increases in the order RA>polidocanol endovenous microfoam>O2:CO2>>CO2-only, 
with foams of a liquid:gas ratio of 1:7 consistently more stable (longer FDTs) than those 
prepared with a 1:4 ratio. Polidocanol endovenous microfoam has a statistically significantly 
higher FDT (close to that of RA) when compared to all CO2-containing PCFs at either liquid:gas 
ratio, prepared by either the DSS or Tessari methods (p<0.035). 
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Foam Half Time (FHT) 
The comparison of FHT for various PCF formulations made using the DSS and Tessari methods 
(1:7 liquid:gas ratio) relative to polidocanol endovenous microfoam was generated by the 
Turbiscan™. Polidocanol endovenous microfoam displayed longer foam half time compared to 
all CO2-containing PCFs, indicating that PEM had greater stability (Figure 8). 
Degradation Rate (DR)/Dwell Time (DT) 
Degradation Rate (DR) was evaluated using a biomimetic vein model to assess the ability of the 
foam to displace a blood substitute. Dwell time (DT) is a more clinically meaningful expression 
of degradation rate as it represents the amount of time that the foam is in contact with the vein 
wall and can act on the endothelium. DT is derived from DR and is calculated as the inverse of 
the DR using the following mathematical expression (refer to Figure 3c): 
[ ])()(
)(
21
12
txtx
tt
DT
−
−
= (1)
The experimental set-up consisted of a segment of polytetrafluorethylene (PTFE) tubing (either 
4 mm or 10 mm in diameter) (Thermo Scientific Inc., USA) filled with a blood substitute and 
fixed to a platform with an adjustable inclination angle (Figure 3a). On initial foam injection, a 
foam plug was formed, which displaced the blood substitute as it travelled upwards along the 
tubing (plug expansion phase) (Figure 3b), while real time video images were captured 
simultaneously. Individual foam plugs were transiently stable and then entered the plug 
degradation phase, during which the plug interface receded towards the initial injection site 
(Figure 3c), ending in complete plug degradation. Videos obtained from both plug expansion and 
degradation phases were analyzed computationally (see Supplementary section S2.4).
25
PCFs of various gas formulations were prepared by DSS or Tessari methods and introduced into 
the biomimetic vein model. The performance of PCFs (1:7 liquid:gas ratio) was compared with 
polidocanol endovenous microfoam, which demonstrated that CO2-containing PCFs, prepared by 
either method and regardless of gas formulation, had DRs faster (12.51 ± 4.49 to 25.81 ± 3.09 
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9 
mm/sec) than that of polidocanol endovenous microfoam (3.43 ± 0.29 mm/sec, p <0.05) (Figure 
S3.1a). Foams prepared using RA were also less cohesive and degraded more rapidly (6.05 ± 
1.79 to 11.22 ± 1.72 mm/sec) than polidocanol endovenous microfoam, although for RA made 
using DSS, this trend was not statistically significant (Figure S3.1a). Polidocanol endovenous 
microfoam was also compared with selected PCF formulations produced using the DSS method 
at liquid:gas ratios of 1:4 and 1:7 (Figure S3.1b). Again, polidocanol endovenous microfoam had 
a statistically lower DR compared with all other CO2-based PCFs regardless of gas ratio (p<0.04) 
and a non-statistical trend for lower DR than the RA PCFs. In general, in this model, the PCFs 
made with 1:4 ratios had a trend to lower DR than the corresponding PCFs made at 1:7 ratio. 
This is contrary to the findings for FDT for the equivalent PCFs. Polidocanol endovenous 
microfoam had the longest DT, almost twice that of PCFs using RA and approximately eight 
times better than PCFs prepared using equivalent gas mixtures (Figures 9a and 9b). 
Discussion
For many years, physicians have compounded RA foams. However, lack of foam homogeneity 
can affect the viscosity and stability of these products. Broad bubble size distributions promote 
foam coarsening and degradation, whilst the lack of solubility of nitrogen in the blood results in 
isolated bubbles persisting in the circulation. Foams with smaller, more uniform bubble size 
possess a lower degradation rate, indicative of a more cohesive and stable foam that should 
ensure better contact with the endothelium of the vessel wall when injected into the vein. The 
ideal foam, then, should be durable enough to allow injection before separating into its gas and 
liquid components, yet short-lived enough to break down once injected. In this study, we 
compared methods for determining bubble size and bubble size distribution of foam formulations 
commonly used in vein treatment as well as methods to establish how the foam bubble size 
characteristics are related to the stability and cohesive nature of the foam. The optical image 
analysis method is an established method for static foam bubble sizing and bubbles size 
distribution measured for freshly-generated foam within its delivery syringe. The Sympatec 
method is a convenient tool for generating foam bubble size distribution and permits multiple 
measurements with differing time delays, while Turbiscan™ permits the measurement of foam 
coarsening on a continuous basis. 
Page 9 of 49 Phlebology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
10 
Regardless of measurement technique, we noted consistent differences between foam 
formulations. RA PCFs produce foams with smaller bubbles, which are inherently more stable, 
but due to the insolubility of nitrogen carry a higher risk of transient ischemic attack (TIA).
26
Replacement of RA with CO2 results in PCFs with increased initial bubble size distribution and 
increasingly rapid coarsening with increasing CO2 content. Polidocanol endovenous microfoam 
produces foams of smaller bubble size and narrower distribution, which is more comparable with 
RA than CO2-containing PCFs made by either the DSS or Tessari method (Figures 5 and 6). 
Therefore, polidocanol endovenous microfoam may have the safety benefit of absorbability 
because of the absence of nitrogen and the efficacy of stable small bubble foam. Polidocanol 
endovenous microfoam produces no large bubbles (Figure 6), unlike the DSS and Tessari 
methods. The neurologic disturbances reported with foam sclerotherapy might to be related to 
gas embolisms that originate from the foam
12, 15, 27
 although this might not be the only factor, as
recent evidence suggests a role for the release of endothelin-1
28
 and histamine
29
 in these
disturbances but remains hypothetical. In contrast, when CO2 replaced air the frequency of 
bubbles seen on transcranial Doppler did not reduce but the symptoms were almost eliminated,
27
and in the few reported cases where urgent CT scanning was performed following onset of 
neurological incident, gas was found replacing the contents of the vertebral or middle cerebral 
artery and in the cerebral venous drainage;
15, 16
 the causal relationship seems inescapable.
Similarly in a study by Regan et al. where O2:CO2 foam was used in patients with proven right-
to-left shunt, despite many patients with bubble emboli, no significant neurological events 
occurred
22
 illustrating the benign nature of small rapidly absorbing bubbles. To complete the
picture, a similar study needs to be conducted using air based foam. 
In the foam drainage studies, polidocanol endovenous microfoam performed similarly to RA 
PCFs (Figures 7b and 7c), consistent with previous observations of similarities in bubble size 
and distribution for both foam types.
25
 For PCFs containing higher proportions of CO2, initial
foam drainage was rapid (Figure 7a). This leads to initial high percentages of liquid drainage 
(first phase) and rapid attainment of an equilibrium position (just tens of seconds to reach the 
slower phase), whereas the relatively dry foam consisting of large bubbles has an inability to 
sustain the higher drainage rates warranted by the larger bubble growth. Figure 7c shows the 
relationship between gas composition of the foam prepared by the polidocanol endovenous foam 
technique, DSS, or Tessari methods and with two different liquid to gas ratios (1:7 and 1:4) and 
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11 
foam drainage time. Drier foams (1:7 liquid:gas ratio) take longer to drain than corresponding 
wetter foams (1:4 ratio), which are most frequently used clinically. Wetter foams will contain 
bigger fluid channels between the bubbles, which pose less resistance to fluid flow under gravity; 
capillary forces will also be lower, resulting in faster drainage. 
Foam Half Time (FHT) results showed relative consistency with FDT. The influential variables 
again were the methods used to generate the foams (polidocanol endovenous microfoam vs DSS 
vs Tessari) and the foam gas formulations, which followed the same trends observed for foam 
drainage, i.e. reduced stability with increasing CO2 content (Figure 8). The reproducibility of the 
results using Turbiscan™ was good, with relatively small standard deviation in the data. This 
validates the Turbiscan™ as a useful and convenient tool for generating FHT data in addition to 
dynamic foam drainage. Foam stability measurements using a vertically standing column of 
foam, however, only partly convey the physical requirements for useful foam. When injected 
into an incompetent vein, the sclerosing foam must ensure good contact with the vessel 
endothelial lining while displacing blood volume. 
It is recognised that the characteristics of sclerosing foams for the treatment of varicose veins 
may be a major determinant of efficacy and safety,
3
 a unique in vitro biomimetic model was
therefore developed to determine the behavior of foam under clinically relevant conditions. This 
model allows for an assessment of the liquid-displacing capability of the foam and its subsequent 
rate of degradation within the vessel. In other measures of stability, RA foam performed best, but 
in the biomimetic model polidocanol endovenous microfoam had the slowest DR, almost half 
that of RA and eight times better than DSS and Tessari-equivalent gas mixtures (Figure S3.1). 
Dwell time (DT), a more meaningful expression of these data, characterizes the length of time 
the foam plug stays in contact with the vein wall. Polidocanol endovenous microfoam had a DT 
twice as long as PCF generated with room air (Figure 9). In a previous report, sufficient practical 
details were disclosed so that this method whether manually performed or with the aid of 
computerized image analysis could be reproduced, introducing a new parameter - degradation 
rate - to be used as a standard to quantify the cohesiveness of foams.
25
 In addition, the
biomimetic analysis system may be of value to researchers and clinicians to gain a deeper 
understanding of the physical parameters governing foam performance, ultimately leading to the 
determination of optimal foam for differing vein diameters and venous disorders. 
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Technical Limitations and Future Perspectives 
In the present study, we performed a range of experiments to compare the performance of PCFs 
with PEM. There were some practical limitations to the study due to the time required to 
manipulate the foam and place it into the instrument before taking a measurement. This was 
generally 30-40 seconds for most techniques which meant the foam had already undergone some 
degradation; this is however, likely to be the time it would take a physician to administer the 
foam into the vein in clinical practice. Despite the wide range of experimental conditions 
investigated, the effect of several parameters has not been examined and could be the subject of 
future investigations. One such area involves the effect of the physical properties of carrier fluids 
on the stability/cohesiveness of sclerosing foams. Experiments using fluids of varying viscosity 
or physiological fluids (i.e., plasma or whole blood) may be performed and could be of interest 
due to the deactivation effects of biological fluids on sclerosants. However, this would require 
optimization of existing techniques for characterising foam stability. Another area of possible 
investigation involves the effect of clinically relevant parameters such as foam injection rate on 
foam stability/cohesiveness. A third avenue of research could involve a more extensive 
investigation of the effect of different sclerosing agents (i.e., such as sodium tetradecyl sulphate 
or alcohol) and their concentration on foam stability/cohesiveness. 
Conclusion 
Polidocanol foams are not all the same, and it is difficult to compare clinical results unless 
characteristics are known and reproducible. Air foams have good performance but have 
associated risks, with persistent nitrogen bubbles in the circulation. Small bubbles and narrow 
bubble size distribution, with slow drainage and separation times, improves foam performance 
by enhancing stability. The biomimetic vein test produces a new measure of foam performance 
that demonstrates the low degradation rate and longer dwell time of polidocanol endovenous 
microfoam compared to PCFs. The polidocanol endovenous microfoam with O2:CO2, low 
nitrogen gas composition and proprietary foam generation device results in better overall 
performance than PCF in a variety of tests, without the associated risk of high-nitrogen room air 
bubbles.  
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Figure Captions 
Figure 1 Methods for producing physician compounded foams (PCFs) and polidocanol 
endovenous microfoam. In the DSS method, syringes are connected by a Combidyn
®
 adapter (a),
while in the Tessari method, they are connected by a three-way valve (b). In both techniques, the 
foam was produced by passing the polidocanol solution (liquid phase) from one syringe, ten 
times into and out of the other syringe initially containing the gas or gas mixture (gaseous 
phase). Foam was produced at room temperature (20°C-22°C). The proprietary canister system 
for generating polidocanol endovenous microfoam (Varithena
®
) is shown in (c).
Figure 2 Methods for measuring bubble size distribution. Sympatec QICPIC image analysis 
sensor (a) and Turbiscan™ LAB apparatus (b). 
Figure 3 Schematic of the biomimetic vein model set-up (a). Foam is injected into the tube over 
time t1 to form a column of length x (mm) (b). On completion of the injection at x = L1, the foam 
degrades over time t2 to a length of x = L2, whereby the degradation rate (DR) and dwell time 
(DT) may be attained (c). CFAS = computational foam analysis system. 
Figure 4 Comparison of glass plate and Sympatec method analyses of polidocanol endovenous 
microfoam. (a) Image of polidocanol endovenous microfoam from the optical image analysis 
method and (b) bubble size distribution measured for this foam; compared to (c) a single frame 
image of the same sample of polidocanol endovenous microfoam captured from the Sympatec 
dynamic image capture method and (d) the bubble size distribution measured by this method 
(over a 15s period, corresponding to 375 image frames). Note how the Sympatec over-reports the 
true bubble size. 
Figure 5 Size distributions of physician compounded foams (DSS vs Tessari) with liquid:gas 
ratio 1:7, obtained using the Sympatec method. Bubble size distribution curves for PCFs using 
different gas formulations (a+d RA; b+e: O2:CO2 of 35:65; c+f 100% CO2) for both the DSS and 
Tessari methods 40s and 115s after foam preparation. Arrows highlight existence of larger 
bubbles in the PCF. RA = room air.  n = 5. 
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17 
Figure 6 Comparison of bubble size distributions at 40s and 115s for polidocanol endovenous 
microfoam (a) compared to PCF O2:CO2 (65:35) made by DSS (b) and Tessari (c) methods. 
Arrows highlight existence of large bubbles in the foam. n = 5. 
Figure 7 Example foam drainage time curves used to measure FDT (a); FDT for DSS versus 
Tessari, and compared with polidocanol endovenous foam (b); FDT for different PCFs made 
using the DSS method at 1:4 and 1:7 liquid to gas ratios, and compared with polidocanol 
endovenous microfoam (c). RA = room air; PEM = polidocanol endovenous microfoam; FDT = 
foam drainage time. Standard deviation ranged from 0.37% to 5.58% of the mean (n = 4). 
Figure 8 Comparison of the foam half time (Turbiscan™) for various physician compounded 
foam (PCF) formulations made using DSS and Tessari methods (1:7 liquid:gas ratio) and foam 
half time for polidocanol endovenous microfoam. Polidocanol endovenous foam displayed a 
longer FHT than CO2-containing PCFs. FHT = foam half time; RA = room air; PEM = 
polidocanol endovenous microfoam. n = 5. 
Figure 9 Polidocanol endovenous microfoam had the longest calculated dwell time, almost twice 
that of PCFs using RA and approximately eight times better than PCFs prepared using equivalent 
gas mixtures in a biomimetic model. RA = room air; PEM = polidocanol endovenous 
microfoam. n = 4.
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List of Tables 
Table I – Summary of the methods of foam characterization employed in the present study. 
Equipment Analysis Supplier 
Glass plate method 
Bubble Size and Bubble Size 
Distribution 
In-house method developed at 
BTG 
Sympatec QICPIC 
Bubble Size and Bubble Size 
Distribution 
Sympatec Ltd, Bury, 
Lancashire, UK 
Turbiscan™ LAB FHT & FDT (foam stability) 
Formulaction SAS, L’Union, 
France 
Biomimetic Vein Model 
Foam Dwell 
Time/Degradation Rate (foam 
stability) 
In-house method developed at 
University of Southampton 
Table II – Number of experimental repeats for each foam characterization experiment 
performed. 
Experiment Number of repeats (N) 
Foam Bubble Sizing 5 
Foam Half Time 5 
Foam Drainage Time 4 
Foam Dwell Time 4 
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Table III – Selected p-values obtained from pairwise statistical comparisons between PEM and 
PCFs foams (p-value << 0.01 indicates values lower than 0.001). 
Foam formulations p-values 
Foam Drainage Time (FDT, Figure 7) 
PEM vs DSS (1:7) 0.01 < p < 0.05 (=0.033) 
PEM vs Tessari (1:7) p << 0.01 
PEM vs DSS (1:4) 0.01 < p < 0.05 (=0.0012) 
PEM vs Tessari (1:4) p << 0.01 
Foam Half Time (FHT, Figure 8) 
DSS (combined) vs Tessari (combined) 0.01 < p < 0.05 (=0.045) 
PEM vs DSS RA (1:7) p << 0.01 
PEM vs DSS 65:35 O2:CO2 (1:7) p > 0.05 
PEM vs DSS 35:65 O2:CO2 (1:7) p << 0.01 
PEM vs DSS 30:70 O2:CO2 (1:7) p << 0.01 
PEM vs DSS 23:77 O2:CO2 (1:7) p << 0.01 
PEM vs DSS 100 CO2 (1:7) p << 0.01 
Dwell Time (DT, Figure 9) 
PEM vs DSS RA (1:7) 0.01 < p < 0.05 (=0.018) 
PEM vs DSS 65:35 O2:CO2 (1:7) p << 0.01 
PEM vs DSS 35:65 O2:CO2 (1:7) p << 0.01 
PEM vs DSS 30:70 O2:CO2 (1:7) p << 0.01 
PEM vs DSS 23:77 O2:CO2 (1:7) p << 0.01 
PEM vs DSS 100 CO2 (1:7) p << 0.01 
PEM vs Tessari RA (1:7) p << 0.01 
PEM vs Tessari O2:CO2 (1:7) p << 0.01 
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PEM vs Tessari 35:65 O2:CO2 (1:7) p << 0.01 
PEM vs Tessari 30:70 O2:CO2 (1:7) p << 0.01 
PEM vs Tessari 23:77 O2:CO2 (1:7) p << 0.01 
PEM vs Tessari 100 CO2 (1:7) p << 0.01 
PEM vs DSS RA (1:4) p < 0.01 (=0.0054) 
PEM vs DSS 65:35 O2:CO2 (1:4) p << 0.01 
PEM vs DSS 35:65 O2:CO2 (1:4) p << 0.01 
PEM vs DSS 100 CO2 (1:4) p << 0.01 
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List of Figures 
Figure 1 
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Figure 2 
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Figure 3 
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Figure 4 
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Figure 5 
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S1 Methods of foam preparation 
S1.1 Preparation of Physician Compounded Foams (PCFs) 
Polidocanol (Shasun Pharma Solutions Ltd, Dudley, Northhumberland, UK) was formulated 
as a 1% buffered saline solution containing 4.2% ethanol and was used as a detergent-type 
sclerosing agent throughout these studies. PCFs were produced by either Double Syringe 
System (DSS) or Tessari methods. The DSS-Tessari method (DSS method for short from 
herein) is a variation of the Tessari method developed by Lorenzo Tessari [1]. 
The DSS foam was produced by passing 1 mL polidocanol from a 5 mL syringe (Discardit™ 
II, Becton Dickinson, Erembodegem, Belgium), ten times into and out of a 10 mL syringe 
containing 7 mL of gas. Syringes were interfaced via a straight connector (equivalent, 
Female-to-Female Luer Lock Connector, QOSINA Edgewood, NY, USA). The Double 
Syringe System remains a popular method employed by the physician to produce sclerosing 
foams [2]. The physician may use a combination of 2, 5 or 10 mL syringes when making the 
foam. A photograph of the Double Syringe System (DSS) is shown in figure S1.1. 
Figure S1.1: Image of the Double Syringe System (DSS). 
For the Tessari method, the straight connector is replaced with a 3-way valve (BD 
Connecta™ 3-Way Stopcocks, Becton Dickinson, Erembodegem, Belgium). A further 
modification involves setting the valve tap at a 30º angle to increase shear when passing the 
foam between the syringes [3][4], which was adopted in the present study. As with the DSS 
method, 5 and 10 mL syringes were used to prepare the foam. A photograph of the Tessari 
system is shown in figure S1.2. 
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Figure 4: Schematic of the Tessari method 
Figure S1.2: Image of the Tessari system. 
A 5 µm filter is sometimes placed between either the 5 or 10 mL syringe and the straight 
connector (in the DSS method) or 3-way valve (in the Tessari method) [5][6]. A filter was not 
used in the preparation of PCFs in these studies. 
S1.2 Preparation of Polidocanol Endovenous Microfoam (PEM) 
PEM is a combination drug device product in development by Provensis Ltd. (a BTG 
International Group Company, London, UK) consisting of a proprietary 65:35 O2:CO2 gas 
mixture with ultralow nitrogen content (<0.8%) and 1% polidocanol solution (no additional 
stabilisers are added), contained within a pressurised canister and combined on discharge 
from the canister as a uniform microfoam. Sterile canisters of the product were used as per 
the instructions for use (IFU), to generate 5 mL of microfoam for experimentation. The 
microfoam was drawn from the canister via a Microfoam Transfer Unit (MTU) into a 10 mL 
Norm-Ject syringe (Henke-Sass Wolf, Tuttlingen, Germany). All the analysis was done on 
the foams recovered from the canisters as described. Every effort was used to minimise the 
time between the discharge of the foam into the syringe and the analysis. 
[1] Tessari L. Tessari method for foam sclerotherapy (10 years of history of technology that 
changed the world of phlebology). XVI World Congress of the Union Internationale de 
Phlebologie, Monaco, 2009 abstract # AP1.7-7 
[2] Hamel-Desnos C, Desnos P, Wollmann JC, et al. Evaluation of the efficacy of 
polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater 
saphenous vein: Initial results. Dermatol Surg. 2003; 29:1170–5 
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[3] Cavezzi A, Tessari L. Foam sclerotherapy techniques: different gases and methods of 
preparation, catheter versus direct injection. Phlebology. 2009; 24(6):247-51 
[4] Mauriello J, Foam Sclerotherapy with other Gases. www.angioadvancements.com 
[5] Shirazi AR, Goldman MP. The use of a 5-micron filter hub increases foam stability when 
using the double syringe technique. Dermatol Surg 2008; 34:91–2 
[6] Hill D. Effect of a 5 micron filter on CO2 sclerosant foam stability. XVI World Congress 
of the UIP. Monaco, 31 August - 4 September 2009 
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S2 Methods of foam characterization 
S2.1 Glass plate method 
Optical image analysis of 2D foams is a well described method of capturing and measuring 
bubble size and bubble size distribution [1]. An aliquot of freshly generated foam (49 µL) 
was placed on a glass plate and immediately covered by another. The plates are thick enough 
not to be distorted and are separated by 32 µm. A flattened monolayer was created, of flat 
cylindrical bubbles 32 µm high. A light microscope and camera (AxioCam ICc 1, Carl Zeiss 
Microscopy, Cambridge,UK), with lighting adjusted to create sharp images of circular 
boundaries, were employed to capture sequential image fields. A built-in software was used 
to “stitch” fields together. Each individual bubble was identified and diameter measured 
using the image analysis (AxioVision, Zeiss) programme with bespoke BubbleSizerMeasure 
macro. In this way between 2000-3000 bubbles were measured. The diameter of these 
flattened bubbles (df) was automatically converted to spherical equivalent diameters (ds), as 
follows: 
( ) ( )
3
1
22 310436
4
1



 −+−+= ππ xxddxd ffs (Eq.1) 
This expression is valid for bubbles greater than the plate separation (which was calibrated 
before each measurement run). Bubbles less than the plate separation remain spherical and 
for these no adjustment was made. A data sheet containing a list of each bubble diameter was 
created for each run. The data are presented as a histogram showing the percentage bubbles 
from a series of images within 15 µm bin size ranges. The Limit of Detection (LOD) for the 
method was set at 11 µm. 
The transfer of foam to the glass plate and the application of the second plate was completed 
in approximately 10 seconds; as the foam was flattened there was no drainage of liquid, and 
bubble size coarsening by gas transfer was greatly reduced such that the time taken to capture 
a series of images was not an issue. Since the purpose of the glass plate method is to capture 
static images and measure bubble size immediately after foam generation, it is unsuitable for 
the measurement of foam dynamics [2]. 
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[1] Pugh RJ. Experimental techniques for studying the structure of foams and froths. 
Advances in Colloid and Interface Science. 2005; 114-115:239-251 
[2] Cheng HC and Lemilch R. Errors in measurement of bubble size distribution in foam. 
Industrial and Engineering Chemistry Fundamentals. 1983; 38:105-109 
S2.2 Sympatec QICPIC 
Bubble size distribution was assessed using a particle size and shape analyser (supplied by 
Sympatec UK, Bury, Lancashire). A 10 mL BD syringe containing either PCF or PEM was 
placed in a syringe pump (Harvard Apparatus PHD/ULTRA, Holliston, MA) and secured. 
The stream of water that carried the bubbles past the detector was driven by peristaltic pump 
(Watson Marlow 505S, Falmouth, UK) set at 35 rpm, which was turned on prior to any 
analysis to clear all the larger air bubbles from the system. The prepared foam was injected 
from the syringe pump at the maximum rate (37.6 mL/min) into the stream of deionised water 
conveyed through a 2 mm cuvette where image analysis software captured images of the 
foam (at 25 frames per second with the detector positioned in the middle of the cuvette). A 
distribution plot of bubble size was reported in the form of a histogram. 
The analysis comprised 5 replicates of 15 second intervals of analysis of the bubbles 
travelling through the cuvette. The time taken from filling of the syringe with foam to 
beginning of the analysis was approximately 35-40 seconds. An initial measurement of 
bubble size was taken immediately after injection of the foam (approximately 40s post foam 
generation), which is clinically-relevant as foam is likely to be injected into the vein within 
that timeframe. We also took an additional measurement at 115s in order to better 
demonstrate how the different foams were coarsening, although this time is less relevant 
clinically as most physicians would make efforts to administer the foam sooner after its 
generation.
S2.3 Turbiscan™ LAB 
The Turbiscan
TM
 LAb (Formulaction SAS, L’Union, France) is an optical analyser that is
capable of multiple light scattering measurements [1]. The system consists of a pulsed near-
infrared light single wavelength source (880 nm) which penetrates the sample, and is detected 
by transmission and backscatter detectors. The level of backscatter (BS) is related to the 
photon mean free path through the foam, and using a software algorithm [2] it can be used to 
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calculate the Sauter Mean Diameter (d32) of the bubble size distribution of the foam using the 
equation: 
( )
2
1
32
13
2
−






−
=
SQg
d
BS
φ
 (Eq.2) 
Where φ is the gas volume fraction, g and Qs are optical factors depending upon d32 and
refractive index [3]. The refractive index of the polidocanol solution used was 1.456 [4] and 
the one of the gas or gas mixture in question was calculated from gas refractive indices 
available from the UK National Physical Laboratory [5]. 
The foam was added carefully to the glass vial via a 21G needle to avoid the introduction of 
additional large bubbles. The light source was fixed at 25 mm above the bottom of the vial 
which represents the middle of the foam sample in the vial. The level of backscatter was 
recorded every second over 2 minutes. Using the Lab
Expert
 software, d32 values for the foam 
were derived from this backscatter data. 
Using the Turbiscan
TM
 LAB the height of liquid accumulated in the vial (55 mm) was
measured automatically scanning the vial every 30 seconds and plotted over time; the time to 
50% drainage (or Foam Half Time, FHT) could be read from the resultant graphs. 
We defined the Foam Drainage Time (FDT) as the time at which liquid first appears at the 
base of the Turbiscan vial. A full vial of foam is placed in the Turbiscan in fixed mode lined 
up with the base of the vial, and the moment of first transmission across the vial detected. 
[1] Mengual O, et al. TURBISCAN MA 2000: multiple light scattering measurement for 
concentrated emulsion and suspension instability analysis. Talanta. 1999; 50(2):445-56 
[2] Mengual O, Meunier G, and Snabre P. Optical characterization of concentrated 
dispersions. On-line process monitoring and control. Recentes progres en genie des procedes. 
2001; 15(84):61-67 
[3] Balerin C, et al. Effect of formulation and processing factors on the properties of liquid 
food foams. Journal of Food Engineering. 2007; 78:802-809 
[4] Sigma Aldrich MSDS Sheet for Polyoxyethylene 4 Lauryl Ether (Polidocanol). Available 
from: http://www.chemistry.mcgill.ca/msds/msds/9002-92-0.pdf 
Page 36 of 49Phlebology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
[5] National Physical Laboratory. Available from: 
www.kayelaby.npl.co.uk/general_physics/2_5/2_5_7.html 
S2.4 Biomimetic Vein Model 
S2.4.1 Experimental set-up 
The cohesiveness of sclerosing foams was investigated within a biomimetic model (Figure 
S2.1). Details of the model specifications have been previously reported [1]. The model 
comprised a segment of 4 mm inner diameter (ID) polytetrafluoroethylene (PTFE) tubing 
(Thermo Scientific Inc., USA) lodged in a straight etching within a rigid bespoke platform at 
a fixed, 25º inclination angle. The great saphenous vein varies in diameter from 2.3 - 4.4 mm 
[2], and therefore we selected 4 mm diameter tubing as this is the upper size and more typical 
of an incompetent vein. A three-way stopcock (Baxter, USA) was placed at the lower end of 
the tube, for sequential tube filling, foam injection and tube flushing. A ruler was attached to 
the platform surface for image calibration, and a high speed CCD camera was used to capture 
real time videos of foam plug expansion and degradation, at a temporal resolution of 30 ms. 
Figure S2.1 Photograph of the experimental set-up. PTFE tubing in a platform (1) stabilised within a 
manifold (2). Platform angle was measured by a digital inclinometer (3). A three-way stopcock at the 
lower end of the tube allowed sequential tube filling, foam injection and tube flushing (4). (Taken 
from Ref. [1]) 
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S2.4.2 Experimental protocols 
The tube was filled with a blood substitute (30% v/v glycerol in purified water), with 
dynamic viscosity of 0.003 Pa×sec and density of 1078 kg/m
3
, which are comparable with the
bulk values for blood [3]. The average injected volume of foam was 1.29 ± 0.18 mL. Upon 
initial foam injection a foam plug was formed, which displaced the blood substitute as it 
travelled upwards along the tubing, and real time video images were captured simultaneously. 
Individual foam plugs were transiently stable, followed by degradation during which the plug 
interface receded towards the initial injection site, until complete plug degradation. Videos 
obtained from both plug expansion and degradation phases were transferred to a personal 
computer (PC) and analysed offline as described below. 
S2.4.3 Computational foam analysis system 
An in-house software was developed using MATLAB (The Mathworks Inc., USA) to 
determine foam degradation rate from the acquired experimental videos. Details about the 
software have been reported in a previous publication [1], and are briefly described below. 
- A video in Audio Video Interleave (AVI) format was loaded and each individual 
frame was automatically extracted. 
- Two reference points on the ruler were manually selected by graphical input function, 
allowing for precise determination of tube inclination angle, image rotation and 
dimensional calibration (conversion from pixel units into physical units; e.g., 
millimetres). 
- A Region Of Interest (ROI) on the images was selected for processing, which 
contained only the segment of the tube where the foam plug was present. 
- Linear mapping was performed to optimise image contrast. Images were subsequently 
converted to black and white (B/W) binary format by thresholding. The resulting 
foam plug then appeared as a white surface in a black background. 
- An analysis line was manually defined for the detection of the plug-fluid interface. 
This was located between the tube centreline and tube base. The code automatically 
read pixel intensity values along the analysis line and located the foam-fluid interface 
at the point of intensity discontinuity (i.e., pixel value varied from 1 to 0 at the 
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interface). This step allowed accurate determination of plug length and the calculation 
of plug volume. 
- The plug volume–time trend was plotted automatically after completion of the video 
processing. By manually selecting two points on the degradation curve, the code 
calculated the plug degradation rate (DR, mm/sec) by linear interpolation of the 
experimental data points located within the selected interval. The interpolating 
function for the degradation phase was determined by least square method. Dwell 
time (DT) was then calculated as the inverse of DR. 
[1] Carugo D, et al. A novel biomimetic analysis system for quantitative characterisation of 
sclerosing foams used for the treatment of varicose veins. J Mater Sci Mater Med. 2013; 
24(6):1417-1423. 
[2] Spivack DE, Kelly P, Gaughan JP, van Bemmelen PS, Mapping of superficial extremity 
veins: normal diameters and trends in a vascular patient-population. Ultrasound Med Biol. 
2012; 38(2): 190-4. 
[3] Pries A, Neuhaus D, Gaehtgens P. Blood viscosity in tube flow: dependence on diameter 
and hematocrit. Am J Physiol. 1992; 263(6):H1770–8. 
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S3 Foam degradation rate (DR)
Figure S3.1 Polidocanol endovenous foam has a lower DR than any PCF, including foams 
made using RA (p<0.035) (a). The same result was obtained at different liquid to gas ratios 
(1:4 and 1:7 liquid:gas) using the DSS method (b). 100% CO2 foams were least stable in all 
tests performed and different O2:CO2 mixtures had intermediate performance. The Tessari 
method produced consistently less stable foams than DSS method. Polidocanol endovenous 
foam was more stable than foam made by either PCF method. RA = room air; DR = 
degradation rate; PEM = polidocanol endovenous microfoam.
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Methods for producing physician compounded foams (PCFs) and polidocanol endovenous microfoam. In the 
DSS method, syringes are connected by a Combidyn® adapter (a), while in the Tessari method, they are 
connected by a three-way valve (b). In both techniques, the foam was produced by passing the polidocanol 
solution (liquid phase) from one syringe, ten times into and out of the other syringe initially containing the 
gas or gas mixture (gaseous phase). Foam was produced at room temperature (20°C-22°C). The 
proprietary canister system for generating polidocanol endovenous microfoam (Varithena®) is shown in 
(c).    
184x262mm (300 x 300 DPI) 
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Methods for measuring bubble size distribution. Sympatec QICPIC image analysis sensor (a) and Turbiscan™ 
LAB apparatus (b).  
142x110mm (300 x 300 DPI)  
Page 42 of 49Phlebology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Comparison of bubble size distributions at 40s and 115s for polidocanol endovenous microfoam (a) 
compared to PCF O2:CO2 (65:35) made by DSS (b) and Tessari (c) methods.  Arrows highlight existence of 
large bubbles in the foam. n = 5.  
184x120mm (300 x 300 DPI)  
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Comparison of glass plate and Sympatec method analyses of polidocanol endovenous microfoam. (a) Image 
of polidocanol endovenous microfoam from the optical image analysis method and (b) bubble size 
distribution measured for this foam; compared to (c) a single frame image of the same sample of 
polidocanol endovenous microfoam captured from the Sympatec dynamic image capture method and (d) the 
bubble size distribution measured by this method (over a 15s period, corresponding to 375 image frames). 
Note how the Sympatec over-reports the true bubble size.  
184x119mm (300 x 300 DPI)  
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Size distributions of physician compounded foams (DSS vs Tessari) with liquid:gas ratio 1:7, obtained using 
the Sympatec method. Bubble size distribution curves for PCFs using different gas formulations (a+d RA; 
b+e: O2:CO2 of 35:65; c+f 100% CO2) for both the DSS and Tessari methods 40s and 115s after foam 
preparation. Arrows highlight existence of larger bubbles in the PCF. RA = room air.  n = 5.  
185x195mm (300 x 300 DPI)  
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Comparison of bubble size distributions at 40s and 115s for polidocanol endovenous microfoam (a) 
compared to PCF O2:CO2 (65:35) made by DSS (b) and Tessari (c) methods.  Arrows highlight existence of 
large bubbles in the foam.  
271x425mm (300 x 300 DPI)  
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Example foam drainage time curves used to measure FDT (a); FDT for DSS versus Tessari, and compared 
with polidocanol endovenous foam (b); FDT for different PCFs made using the DSS method at 1:4 and 1:7 
liquid to gas ratios, and compared with polidocanol endovenous microfoam (c). RA = room air; PEM = 
polidocanol endovenous microfoam; FDT = foam drainage time. Standard deviation ranged from 0.37% to 
5.58% of the mean (n = 4).  
270x584mm (300 x 300 DPI)  
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Comparison of the foam half time (Turbiscan™) for various physician compounded foam (PCF) formulations 
made using DSS and Tessari methods (1:7 liquid:gas ratio) and foam half time for polidocanol endovenous 
microfoam. Polidocanol endovenous foam displayed a longer FHT than CO2-containing PCFs. FHT = foam 
half time; RA = room air; PEM = polidocanol endovenous microfoam. n = 5.  
130x91mm (300 x 300 DPI)  
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Polidocanol endovenous microfoam had the longest calculated dwell time, almost twice that of PCFs using RA 
and approximately eight times better than PCFs prepared using equivalent gas mixtures in a biomimetic 
model. RA = room air; PEM = polidocanol endovenous microfoam. n = 4.  
282x433mm (300 x 300 DPI)  
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